Current and Emerging Technologies to Address the Placebo Response Challenge in CNS Clinical Trials: Promise, Pitfalls, and Pathways Forward

William P. Horan, Gary Sachs, Dawn I. Velligan, Michael Davis, Richard S.E. Keefe, Ni A. Khin, Florence Butlen-Ducuing, Philip D. Harvey

Producción científica: Review articlerevisión exhaustiva

Resumen

Excessive placebo response rates have long been a major challenge for central nervous system (CNS) drug discovery. As CNS trials progressively shift toward digitalization, decentralization, and novel remote assessment approaches, questions are emerging about whether innovative technologies can help mitigate the placebo response. This article begins with a conceptual framework for understanding placebo response. We then critically evaluate the potential of a range of innovative technologies and associated research designs that might help mitigate the placebo response and enhance detection of treatment signals. These include technologies developed to directly address placebo response; technology-based approaches focused on recruitment, retention, and data collection with potential relevance to placebo response; and novel remote digital phenotyping technologies. Finally, we describe key scientific and regulatory considerations when evaluating and selecting innovative strategies to mitigate placebo response. While a range of technological innovations shows potential for helping to address the placebo response in CNS trials, much work remains to carefully evaluate their risks and benefits.

Idioma originalEnglish (US)
Páginas (desde-hasta)19-30
Número de páginas12
PublicaciónInnovations in Clinical Neuroscience
Volumen21
N.º1-3
EstadoPublished - ene 1 2024

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Huella

Profundice en los temas de investigación de 'Current and Emerging Technologies to Address the Placebo Response Challenge in CNS Clinical Trials: Promise, Pitfalls, and Pathways Forward'. En conjunto forman una huella única.

Citar esto